Drug intelligence / Profile preview

BB-1708

Development stage: Preclinical
Lead developer: Bliss Media
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

BB-1708 is an antibody-drug conjugate (ADC) developed by Bliss Biopharmaceutical (Hangzhou) for the treatment of neoplasms, specifically solid tumors. As an ADC, it consists of a monoclonal antibody linked to a cytotoxic agent, designed to selectively deliver the cytotoxic payload to tumor cells expressing the target antigen. The drug is currently in preclinical development and has not yet entered clinical trials or received regulatory approval[1][2]. Detailed information about its specific molecular target, payload, and linker technology has not been disclosed publicly.

Beyond the preview

Go deeper on BB-1708.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BB-1708.

Explore the full profile